NEW YORK – Invitae said after the close of the market on Thursday that it has priced an underwritten public offering of 7,766,990 shares of its common stock at $51.50 per share.
The molecular diagnostics firm expects gross proceeds of approximately $400 million from the offering, which it announced on Wednesday. Invitae has also granted underwriters a 30-day option to purchase an additional 1,165,048 shares of its common stock at the public offering price.